Cargando…

Gender disparities in diabetes and coronary heart disease medication among patients with type 2 diabetes: results from the DIANA study

BACKGROUND: Coronary heart disease (CHD) is one of the most common long-term complications in people with type 2 diabetes. We analyzed whether or not gender differences exist in diabetes and CHD medication among people with type 2 diabetes. METHODS: The study was based on data from the baseline exam...

Descripción completa

Detalles Bibliográficos
Autores principales: Krämer, Heike U, Raum, Elke, Rüter, Gernot, Schöttker, Ben, Rothenbacher, Dietrich, Rosemann, Thomas, Szecsenyi, Joachim, Brenner, Hermann
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3526520/
https://www.ncbi.nlm.nih.gov/pubmed/22838970
http://dx.doi.org/10.1186/1475-2840-11-88
_version_ 1782253579585716224
author Krämer, Heike U
Raum, Elke
Rüter, Gernot
Schöttker, Ben
Rothenbacher, Dietrich
Rosemann, Thomas
Szecsenyi, Joachim
Brenner, Hermann
author_facet Krämer, Heike U
Raum, Elke
Rüter, Gernot
Schöttker, Ben
Rothenbacher, Dietrich
Rosemann, Thomas
Szecsenyi, Joachim
Brenner, Hermann
author_sort Krämer, Heike U
collection PubMed
description BACKGROUND: Coronary heart disease (CHD) is one of the most common long-term complications in people with type 2 diabetes. We analyzed whether or not gender differences exist in diabetes and CHD medication among people with type 2 diabetes. METHODS: The study was based on data from the baseline examination of the DIANA study, a prospective cohort study of 1,146 patients with type 2 diabetes conducted in South-West Germany. Information on diabetes and CHD medication was obtained from the physician questionnaires. Bivariate and multivariate analyses using logistic regression were employed in order to assess associations between gender and prescribed drug classes. RESULTS: In total, 624 men and 522 women with type 2 diabetes with a mean age of 67.2 and 69.7 years, respectively, were included in this analysis. Compared to women, men had more angiopathic risk factors, including smoking, alcohol consumption and worse glycemic control, and had more often a diagnosed CHD. Bivariate analyses showed higher prescription of thiazolidinediones and oral combination drugs as well as of angiotensin-converting enzyme (ACE) inhibitors, calcium channel blockers and aspirin in men than in women. After full adjustment, differences between men and women remained significant only for ACE inhibitors (OR = 1.44; 95%-confidence interval (CI): 1.11 – 1.88) and calcium channel blockers (OR = 1.42, 95%-CI: 1.05 – 1.91). CONCLUSIONS: These findings contribute to current discussions on gender differences in diabetes care. Men with diabetes are significantly more likely to receive oral combination drugs, ACE inhibitors and calcium channel blockers in the presence of coronary heart disease, respectively. Our results suggest, that diabetic men might be more thoroughly treated compared to women. Further research is needed to focus on reasons for these differences mainly in treatment of cardiovascular diseases to improve quality of care.
format Online
Article
Text
id pubmed-3526520
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-35265202012-12-20 Gender disparities in diabetes and coronary heart disease medication among patients with type 2 diabetes: results from the DIANA study Krämer, Heike U Raum, Elke Rüter, Gernot Schöttker, Ben Rothenbacher, Dietrich Rosemann, Thomas Szecsenyi, Joachim Brenner, Hermann Cardiovasc Diabetol Original Investigation BACKGROUND: Coronary heart disease (CHD) is one of the most common long-term complications in people with type 2 diabetes. We analyzed whether or not gender differences exist in diabetes and CHD medication among people with type 2 diabetes. METHODS: The study was based on data from the baseline examination of the DIANA study, a prospective cohort study of 1,146 patients with type 2 diabetes conducted in South-West Germany. Information on diabetes and CHD medication was obtained from the physician questionnaires. Bivariate and multivariate analyses using logistic regression were employed in order to assess associations between gender and prescribed drug classes. RESULTS: In total, 624 men and 522 women with type 2 diabetes with a mean age of 67.2 and 69.7 years, respectively, were included in this analysis. Compared to women, men had more angiopathic risk factors, including smoking, alcohol consumption and worse glycemic control, and had more often a diagnosed CHD. Bivariate analyses showed higher prescription of thiazolidinediones and oral combination drugs as well as of angiotensin-converting enzyme (ACE) inhibitors, calcium channel blockers and aspirin in men than in women. After full adjustment, differences between men and women remained significant only for ACE inhibitors (OR = 1.44; 95%-confidence interval (CI): 1.11 – 1.88) and calcium channel blockers (OR = 1.42, 95%-CI: 1.05 – 1.91). CONCLUSIONS: These findings contribute to current discussions on gender differences in diabetes care. Men with diabetes are significantly more likely to receive oral combination drugs, ACE inhibitors and calcium channel blockers in the presence of coronary heart disease, respectively. Our results suggest, that diabetic men might be more thoroughly treated compared to women. Further research is needed to focus on reasons for these differences mainly in treatment of cardiovascular diseases to improve quality of care. BioMed Central 2012-07-27 /pmc/articles/PMC3526520/ /pubmed/22838970 http://dx.doi.org/10.1186/1475-2840-11-88 Text en Copyright ©2012 Krämer et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Investigation
Krämer, Heike U
Raum, Elke
Rüter, Gernot
Schöttker, Ben
Rothenbacher, Dietrich
Rosemann, Thomas
Szecsenyi, Joachim
Brenner, Hermann
Gender disparities in diabetes and coronary heart disease medication among patients with type 2 diabetes: results from the DIANA study
title Gender disparities in diabetes and coronary heart disease medication among patients with type 2 diabetes: results from the DIANA study
title_full Gender disparities in diabetes and coronary heart disease medication among patients with type 2 diabetes: results from the DIANA study
title_fullStr Gender disparities in diabetes and coronary heart disease medication among patients with type 2 diabetes: results from the DIANA study
title_full_unstemmed Gender disparities in diabetes and coronary heart disease medication among patients with type 2 diabetes: results from the DIANA study
title_short Gender disparities in diabetes and coronary heart disease medication among patients with type 2 diabetes: results from the DIANA study
title_sort gender disparities in diabetes and coronary heart disease medication among patients with type 2 diabetes: results from the diana study
topic Original Investigation
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3526520/
https://www.ncbi.nlm.nih.gov/pubmed/22838970
http://dx.doi.org/10.1186/1475-2840-11-88
work_keys_str_mv AT kramerheikeu genderdisparitiesindiabetesandcoronaryheartdiseasemedicationamongpatientswithtype2diabetesresultsfromthedianastudy
AT raumelke genderdisparitiesindiabetesandcoronaryheartdiseasemedicationamongpatientswithtype2diabetesresultsfromthedianastudy
AT rutergernot genderdisparitiesindiabetesandcoronaryheartdiseasemedicationamongpatientswithtype2diabetesresultsfromthedianastudy
AT schottkerben genderdisparitiesindiabetesandcoronaryheartdiseasemedicationamongpatientswithtype2diabetesresultsfromthedianastudy
AT rothenbacherdietrich genderdisparitiesindiabetesandcoronaryheartdiseasemedicationamongpatientswithtype2diabetesresultsfromthedianastudy
AT rosemannthomas genderdisparitiesindiabetesandcoronaryheartdiseasemedicationamongpatientswithtype2diabetesresultsfromthedianastudy
AT szecsenyijoachim genderdisparitiesindiabetesandcoronaryheartdiseasemedicationamongpatientswithtype2diabetesresultsfromthedianastudy
AT brennerhermann genderdisparitiesindiabetesandcoronaryheartdiseasemedicationamongpatientswithtype2diabetesresultsfromthedianastudy